Technology

Patents and Intellectual Property

Four (4) U.S. patents and allowance of claims, and three (3) international patent have been issued covering key aspects of our core technology with patent expirations ranging between 2028 and 2031.

Jurisdiction Title Type and No. Date
U.S. Tumor microenvironment of metastasis (TMEM) and uses thereof in diagnosis, prognosis, and treatment of tumors U.S. Patent No.
8,642,277 B2
2/4/2014
U.S. Metastasis specific splice variants of Mena and uses thereof in diagnosis and prognosis and treatment of tumors U.S. Patent No. 9,719,142 B2  8/1/2017
U.S. Metastasis specific splice variants of Mena and uses thereof in diagnosis and prognosis and treatment of tumors U.S. Patent No. 8,603,738 B2 12/10/2013
U.S. Isolation, gene expression, and chemotherapeutic resistance of motile cancer cells U.S. Patent No.
8,298,756 B2
10/30/2012
Europe Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors EP Patent No.
2 126 566
13/29/2017
Europe Methods for identifying metastasis in motile cells EP Patent No.
1 784 646 
6/13/2012
Canada Isolation, gene expression, and chemotherapeutic resistance of motile cancer cells CA Patent No.
2,576,702
10/4/2016